- Aug 12, 2015

Novel Therapeutic Agent for Pediatric Cancer Developed at UC San Diego in Clinical Trials

Donald L. Durden, MD, PhD, pediatric researcher at University of California, San Diego School of Medicine and Moores Cancer Center has identified and developed a novel therapeutic target for neuroblastoma, the second most common solid-tumor childhood cancer.

Pediatric Cancer Survivors Treated With Abdominopelvic RT Have Higher Risk of CRC

Study shows potential of new treatment strategies for most common childhood cancer

Promising target for CAR T cells helps cancer trick the immune system

Palliative Care Important for Young Patients During ‘Identity Development’

Scientists discover new Achilles heel of leukemia cells

Promising investigational therapy improves survival in aggressive childhood brain tumor

Childhood cancer mortality has fallen significantly in the US, but disparities have emerged

St. Jude scientists identify T-cell differentiation nodes to improve cancer-killing

Analysis shows high rate of ‘significant’ health problems in childhood cancer survivors

Fusion oncoprotein forces cell fates toward rhabdomyosarcoma

Recent Posts

Novel Therapeutic Agent for Pediatric Cancer Developed at UC San Diego in Clinical Trials

Archive

Search By Tags